Cologne, Germany, October 01, 2009 / b3c newswire / - CEVEC Pharmaceuticals, the developer of a novel human expression system derived from amniocytes and the contract manufacturer InVivo BioTech Services GmbH announced today the signing of a strategic license agreement. This license enables InVivo to offer its customers the production of their diagnostic and preclinical grade material very fast and in highest quality, including authentic human glycosylation patterns, using the novel and proprietary CAP-TTM transient expression system.
CAP-TTM Technology is based on CAP® cells, the stable cell line from CEVEC. The non-tumor origin cells have high expression rates of human proteins and grow in serum-free suspension culture and post-translational modifications are human-like. Process times are reduced by means of large-scale transient transfection.
“After launching our new transient cell in the US market we are delighted to have now our first customers in Europe not only using our stable expression system but also working with our new transiently expressing human cell line. With expression rates outperforming any other human system on the market, e.g. HEK 293 freestyle and others, while offering highest quality human like proteins, we offer our customers a unique state of the art cell line,” Wolfgang Kintzel, CCO of CEVEC Pharmaceuticals GmbH states.
Rainer Lichtenberger, CEO of CEVEC, adds. “Because posttranslational modifications play a significant role for the bioactivity of recombinant proteins it is of crucial importance to produce proteins with human-like glycosylation and sialylation. With our proprietary human cell lines, CAP for permanent producer cells for proteins and the novel CAP-T system, only CEVEC is able to offer a unique range of versatile human cell expression systems to our customers, from early discovery to protein manufacture. This license agreement contributes significantly to CEVECs goal becoming the leading cell line supplier for protein production with human cell expression systems.”
About CEVEC Pharmaceuticals GmbH - www.cevec-pharmaceuticals.com
CEVEC Pharmaceuticals GmbH, operational since 2004 was founded by a group of internationally renowned scientists and clinicians from the University of Cologne, Germany. Based on their experience and their longstanding collaborative work they had experienced a lack of innovative expression systems for more efficient production of biologics such as recombinant proteins or gene therapy vectors. CEVEC’s novel proprietary human CAP® and CAP-T™ expression systems are ideal for manufacturing complex biopharmaceutical molecules with human glycosylation patterns.
About InVivo BioTech Services GmbH - www.invivo.de
InVivo is a contract manufacturing organization (CMO) dedicated to the development and production of monoclonal antibodies and expression of recombinant proteins. Based in Hennigsdorf, Germany, just outside Berlin, InVivo is an ISO 9001 certified company with over ten years experience in mammalian cell culture and protein production. More than 1100 different hybridomas have been cultivated in InVivo’s proprietary serum-free media ISF1 for high productivity and cost benefits in cultivation and purification. Furthermore InVivo offers the complete range of modern protein expression techniques. Starting from synthetic or amplified cDNA your protein can be stable expressed in bacteria, insect and mammalian cell lines or alternatively transient expressed.
Contact:
Wolfgang Kintzel
Chief Commercial Officer / Geschäftsführer
CEVEC Pharmaceuticals GmbH
Gottfried-Hagen Straße 62
D-51105 Köln
Germany
fon +49 (0) 221-46 02 08 - 00
fax +49 (0) 221-46 02 08 - 01
This email address is being protected from spambots. You need JavaScript enabled to view it.
www.cevec-pharmaceuticals.com